A Pharmacoepidemiological Study to Examine Patient Characteristics, Drug Utilization Pattern and Crude Incidence Rates of Selected Outcomes in New Users of Ticagrelor, Clopidogrel and Prasugrel in National Swedish Registries
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- AstraZeneca
- 入组人数
- 7,200
- 试验地点
- 1
- 主要终点
- Drug utilization: Description of patient characteristics and drug usage
研究概览
简要总结
The purpose of the study is to describe patient characteristics and drug usage among patients that are prescribed ticagrelor for the first time and to compare them with patients who are prescribed clopidogrel and prasugrel for the first time.
A further purpose is to ascertain and estimate the crude incidence rate of bleeding, arrhythmias, heart failure, acute renal failure, acute liver failure, dyspnoea and gout among new users in the three cohorts of ticagrelor, clopidogrel and prasugrel.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •First time users of ticagrelor, clopidogrel and prasugrel, respectively
排除标准
- •Individuals with more than one of above three antiplatelet drugs dispensed the same day
研究组 & 干预措施
Exposure Group 1
First time users of ticagrelor
干预措施: Risk of selected safety events (Drug)
Exposure Group 2
First time users of clopidogrel
干预措施: Risk of selected safety events (Drug)
Exposure Group 3
First time users of prasugrel
干预措施: Risk of selected safety events (Drug)
结局指标
主要结局
Drug utilization: Description of patient characteristics and drug usage
时间窗: Up to one year after entry into study cohort
次要结局
- Follow-up of safety outcomes: First occurrence of bleeding, arrhythmias, heart failure, acute renal failure, acute liver failure, dyspnoea and gout(Up to one year after entry into study cohort.)